Dermata Therapeutics Inc (DRMA) - Total Assets
Based on the latest financial reports, Dermata Therapeutics Inc (DRMA) holds total assets worth $5.32 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Dermata Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Dermata Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Dermata Therapeutics Inc (DRMA) market capitalisation for the company's overall valuation and market capitalisation.
Dermata Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Dermata Therapeutics Inc's total assets of $5.32 Million consist of 100.0% current assets and 0.0% non-current assets. Review DRMA liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Dermata Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DRMA stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dermata Therapeutics Inc's current assets represent 100.0% of total assets in 2025, an increase from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 95.7% of total assets in 2025, down from 96.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Dermata Therapeutics Inc Competitors by Total Assets
Key competitors of Dermata Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Dermata Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.09 | 3.70 | 0.69 |
| Quick Ratio | 7.00 | 3.70 | 0.69 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.41 Million | $7.30 Million | $-505.80K |
Dermata Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Dermata Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.69 |
| Latest Market Cap to Assets Ratio | 0.59 |
| Asset Growth Rate (YoY) | 122.5% |
| Total Assets | $7.86 Million |
| Market Capitalization | $4.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dermata Therapeutics Inc's assets below their book value (0.59x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dermata Therapeutics Inc's assets grew by 122.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dermata Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Dermata Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.86 Million | +122.53% |
| 2024-12-31 | $3.53 Million | -55.71% |
| 2023-12-31 | $7.98 Million | +14.89% |
| 2022-12-31 | $6.94 Million | -40.26% |
| 2021-12-31 | $11.62 Million | +1819.87% |
| 2020-12-31 | $605.45K | -70.69% |
| 2019-12-31 | $2.07 Million | -- |
About Dermata Therapeutics Inc
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in… Read more